Our ultimate and long-term goal is to identify protective T cell antigens and epitopes that are preferentially recognized by CD4+ and CD8+ T cells from patients who have resolved acute COVID-19 and never developed LC (recovered asymptomatic patients). The gene discussed is CD8A; the disease is laryngotracheoesophageal cleft.